Management Team


Bent U. Frandsen, Chief Executive Officer

Bent Frandsen holds a MSc in Finance and Strategic Planning from Copenhagen Business School, Denmark.

Bent has more than 27 years of professional experience in management, finance, and business development positions in multinational companies, including more than 24 years life science experience at public listed companies: Lundbeck, ALK-Abelló, Coloplast, and private companies: NsGene, CMC Biologics, and Amphidex.

He is experienced in licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals.

Bent Frandsen is employed since 2016 and was appointed CEO in 2019.

Shares: 150,000

Warrants: 400,000


Keith Alexander, Chief Financial Officer

Keith Alexander holds an MBA from The Wharton School of the University of Pennsylvania, and a B.Sc. in Industrial Management, with a minor in Biological Sciences, from Purdue University.

Keith has over 20 years of professional experience in investment markets, investor communications, corporate strategy, and business development from American and Danish banks. Over his career, he has served in leadership, analytical and commercial functions at J.P. Morgan Securities and J.P. Morgan Asset Management in NYC, NY, USA, Danske Bank Asset Management (formerly Danske Capital) in Kongens Lyngby, Denmark and Accenture (formerly Andersen Consulting) in Chicago, IL, USA.

Keith has contributed to raising over €1 billion for equity and bond portfolios, evaluated large M&A transactions, structured and valued cross-border joint ventures, advised investors managing over $8 trillion in assets, and analyzed financial services companies as a member of the #1 ranked All-American Equity Research Team in 2010 at J.P. Morgan Securities.

Keith Alexander is employed since October 2020 and is an American citizen with Danish permanent residence.

Shares: 31,930

Warrants: 100,000


Farshad Guirakhoo, Chief Scientific Officer

Dr. Farshad Guirakhoo holds a PhD in Virology from the Medical University of Vienna, Austria, and an M.Sc. in Genetics from the International Institute for Biophysics and Biochemistry at the University of Tehran.

Farshad has 30+ years of broad translational research experience in the vaccine development field. He joins from his recent positions as Senior Advisor Vaccine Research and Development and CSO of Vaxxinity, Inc. (NASDAQ: VAXX), headquartered in Dallas, Texas. In 2014, Dr. Guirakhoo was named as no. 22 in The Most Influential People in Vaccines. He is the co-inventor of the ChimeriVax™-technology platform, the world’s first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. He is the author of over 100 peer-reviewed publications and holds dozens of issued patents.

Dr. Farshad Guirakhoo has been employed by the company since January of 2023.

Shares: 0

Warrants: 50,000


Mattis Flyvholm Ranthe, Chief Medical Officer

Dr. Mattis F. Ranthe holds a PhD in Cardiovascular Epidemiology (2013), and a Medical Diploma (MD) (2006) from the University of Copenhagen, Denmark.

Mattis brings a decade of broad clinical research experience into the company. He has a solid background as a physician, including managing drug development projects in various biopharmaceutical companies (including Novo Nordisk, ALK, and GSK Vaccines). In all of his medical lead roles he has been instrumental in progressing development programs from preclinical or early clinical stages into human proof of concept and/or pivotal stage phases.

Dr. Mattis F. Ranthe is employed by the company since February of 2022.

Shares: 10,800

Warrants: 100,000


Max M. Søgaard, Senior Vice President of Research & Development and Technology

Dr. Max M. Søgaard holds a PhD in Biochemistry from University College London, UK, and a MSc in Molecular Biology from Aarhus University, Denmark.

Max has 20 years of scientific research and process development experience, having served the last eight years at ExpreS2ion in roles ranging from Senior Scientist (Downstream) to Vice President, and prior to that 12 years of academic research focused on structural biology and molecular biophysics with an emphasis on infectious disease applications. Max heads internal R&D in order to extend ExpreS2ion’s unique capabilities and know-how in applying ExpreS2™ technology for customers and the company's own vaccine development.

Dr. Max M. Søgaard has been employed by the company since 2013 and was appointed Vice President in 2020.

Shares: 74,589

Warrants: 100,000


Mette Thorn, Senior Vice President of Preclinical Development

Dr. Mette Thorn holds a PhD in Immunology and a MSc in Chemical Engineering from the Technical University of Denmark.

Mette has 20 years of preclinical development and management experience in vaccine development within cancer and infectious diseases, amongst other fields. Mette has extensive research science experience from Biotech and Pharma, including from roles with Astion Pharma, the SSI, Symphogen, Novo Nordisk, Bioneer, Biocare, and CBio. In all of her roles she has been instrumental in progressing preclinical pipeline assets from early stage research into clinical development phases.

Dr. Mette Thorn has been employed by the company since February of 2021.

Shares: 800

Warrants: 100,000